EyeWorld Weekly, April 3, 2026

➤ Positive topline data from Phase 3 study for thyroid eye disease treatment ➤ Controlled U.S. release of outflow restoration platform for glaucoma ➤ New platform established to help bring supportive evidence to interventional glaucoma ➤ Head-to-head Phase 1b study supports investigational anti-VEGF ➤ Complimentary access to video journal ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, April 3, 2026